Close

Baird Reiterates a 'Neutral' on Regeneron Pharma (REGN); VIEW 2-Year Data Blurs EYLEA's Differentiation, As Expected Dec 5, 2011 09:32AM
Baird Riterates a 'Neutral' on Regeneron Pharma (REGN); Q311 Uneventful; Still Think Best Case Scenario Is Priced In Nov 1, 2011 07:46AM
Notable Analyst Rating Changes 10/26: (AMTD) (NFLX) (REGN) Upgraded; (HGSI) (FSLR) (MF) Downgraded Oct 26, 2011 11:22AM
Baird Maintains a 'Neutral' on Regeneron Pharma (REGN) Following Roche's Q311 Lucentis Update Oct 13, 2011 11:09AM
Baird Reiterates a 'Neutral' on Regeneron Pharma (REGN); Kills Us to Sit on the Fence, But New Survey Shows That's the Best Place Sep 30, 2011 08:18AM


Aug 17, 2011 11:54AM Baird Maintains a 'Neutral' on Regeneron Pharma (REGN); Updating Model for EYLEA Delay; Remain Cautious
Jun 2, 2011 10:34AM Notable Analyst Rating Changes 06/02: (AFFX) (JNJ) (DV) Upgraded; (GIS) (ES) (SRE) Downgraded
Dec 20, 2010 12:31PM Baird Raises Price Target on Regeneron Pharma (REGN), Maintains Neutral Rating
Sep 24, 2008 07:54AM Baird Initiates Coverage on Regeneron (REGN) with a Neutral